Enanta's 15min chart shows KDJ Golden Cross and Bullish Marubozu signals.

Enanta's 15-minute chart recently exhibited a KDJ Golden Cross and Bullish Marubozu pattern on August 14, 2025, at 12:30. This shift in momentum indicates a potential increase in the stock price, as buyers have gained control of the market. The bullish momentum is likely to continue, suggesting a positive outlook for the stock.

Enanta Pharmaceuticals (NASDAQ:ENTA) has seen a surge in analyst optimism and technical momentum, indicating potential upside for the stock. On August 14, 2025, the company's 15-minute chart exhibited a KDJ Golden Cross and Bullish Marubozu pattern, signaling a shift in market sentiment [1]. This bullish momentum is likely to continue, as buyers have gained control of the market.

Analysts have been increasingly positive about Enanta's prospects. Citizens JMP analyst Roy Buchanan raised the price target on Enanta's stock to $25.00 from $24.00, maintaining a Market Outperform rating [1]. This move comes after Enanta reported fiscal third-quarter 2025 results that exceeded both analyst and consensus expectations, driven by strong revenues and continued expense reductions. The company ended the quarter with $204 million in cash and provided guidance that its cash position and continuing Mavyret income would fund operations into fiscal 2028 [1].

Enanta's next major clinical catalyst will be the Phase 2 results for zelicapavir, its oral N-protein inhibitor for RSV in high-risk adults, expected next month. Management is targeting approximately a one-day improvement in symptom resolution compared to placebo [1].

Additionally, Enanta Pharmaceuticals announced the U.S. Food and Drug Administration’s approval of MAVYRET as an eight-week treatment for acute hepatitis C, achieving a 96% cure rate in clinical trials [1]. This approval broadens the treatment’s indication to include both acute and chronic hepatitis C in adults and children three years and older.

Enanta reported fiscal Q3 2025 revenue of $18.3 million, up a touch year-over-year, mainly from royalties on AbbVie’s hepatitis C drugs MAVYRET and MAVIRET [2]. The company's net loss narrowed to $18.26 million, with operating expenses ending at $37.21 million and an EPS of -$0.85. Enanta’s management says current cash and ongoing royalties should keep the business going through 2028. Wall Street agrees things are looking up: the consensus is ‘buy,’ with a median 12-month price target of $20 per share—almost 66% above the $6.90 closing price on August 8 [2].

Investors should pay close attention to Enanta's upcoming data releases and clinical trial results, as these could significantly impact the stock's performance. With four of six analysts rating the stock a ‘buy’ or ‘strong buy’ and a price target well above the recent share price, there’s renewed optimism for a stock rebound [2].

References:

[1] https://za.investing.com/news/analyst-ratings/citizens-jmp-raises-enanta-pharmaceuticals-stock-price-target-to-25-from-24-93CH-3833274
[2] https://finimize.com/content/enanta-pharmaceuticals-sees-narrower-losses-and-brighter-analyst-views